Latest news with #VVT
Cision Canada
4 days ago
- Business
- Cision Canada
VVT Med Inc. Engages Independent Trading Group as Market Maker
TORONTO, Aug. 13, 2025 /CNW/ - VVT Med Inc. (TSXV: VVTM) (" VVT" or the " Company"), announces that it has entered into a market making service agreement (the " Agreement") with Independent Trading Group (" ITG") dated August 13, 2025. Pursuant to the Agreement, ITG will provide market-making services in accordance with TSX Venture Exchange (the " TSVX") policies and will trade shares of the Company on the TSXV and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the Company's common shares. The Agreement is subject to final approval from the TSXV. ITG will receive compensation of CAD$5,000 per month, payable monthly in advance. The Agreement is for an initial term of one month and will renew for additional one-month terms unless terminated. The Agreement may be terminated by either party with 30 days' notice. There are no performance factors contained in the Agreement and ITG will not receive shares or options as compensation. ITG and the Company are unrelated and unaffiliated entities and at the time of the Agreement, neither ITG nor its principals have an interest, directly or indirectly, in the securities of the Company. About Independent Trading Group Independent Trading Group (ITG) Inc. is a Toronto based CIRO dealer-member that specializes in market making, liquidity provision, agency execution, ultra-low latency connectivity, and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high quality liquidity provision and execution services to a broad array of public issuers and institutional investors. About VVT Med Inc. VVT develops, manufactures, and commercializes minimally invasive, non-thermal, and non-tumescent solutions for the treatment of varicose veins. VVT's products offer several key competitive advantages over traditional alternatives, including faster treatment times, reduced pain without the need for anesthesia, and quicker recovery and results. Cautionary Note Regarding Forward-Looking Statements This news release contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this document include, among others, statements with respect to the engagement of ITG including the duration and TSXV approval of such engagement. Such statements and information reflect the current view of the Company. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Cision Canada
31-07-2025
- Business
- Cision Canada
VVT Med Inc. Announces Commencement of Trading on TSX Venture Exchange
TORONTO, /CNW/ - VVT Med Inc. (TSXV: VVTM) (the " Company") is pleased to announce that the Company's common shares will commence trading on the TSX Venture Exchange (the " TSXV") at the opening of market on July 31, 2025 under the symbol "VVTM". The Company's listing on the TSXV follows the previously announced reverse-takeover transaction with V.V.T. Med Ltd. and Exiteam Acquisition Corp. pursuant to the terms of a definitive agreement dated September 30, 2024 (the " Transaction"). For more information about the Transaction, please see the Company's press release dated July 22, 2025 and Filing Statement dated May 15, 2025, which are available under the Company's SEDAR+ profile at The Transaction As consideration, each ordinary share of VVT (" VVT Share") was exchanged for common shares of the Company (the " Company Shares") on the basis of the exchange ratio for the VVT Shares set out in the Definitive Agreement. Each common share of EAC (" EAC Share") was exchanged for one Company Share. Any outstanding warrants or other exchangeable or convertible securities of EAC and VVT were exchanged, on an equivalent basis, for securities of the Company. Pursuant to the Transaction: (i) 2,053,571 Company Shares were issued to creditors of the Company in settlement of $1,150,000 of debt, at a deemed price of $0.56 per Company Share, pursuant to certain debt settlement agreements dated June 30, 2025; (ii) 14,068,876 Company Shares were issued in exchange for the outstanding EAC Shares (including 6,955,498 Company Shares issued to holders of EAC subscription receipts); and (iii) 47,915,074 Company Shares were issued to holders of the VVT Shares (including those issued upon conversion of the outstanding VVT convertible debentures). Additionally, the Company has the following convertible securities issued and outstanding following the closing of the Transaction: (i) 1,553,651 stock options to purchase Company Shares; (ii) 23,199,131 common share purchase warrants to purchase Company Shares; and (iii) 299,915 broker warrants to purchase Company Shares. Following the Transaction, there are 66,640,102 Company Shares issued and outstanding. For further details regarding the capitalization of the Company, please see the Filing Statement. Escrowed Shares In connection with the Transaction, certain shareholders of the Company have entered into a Tier 2 Value Escrow Agreement with the Company and Computershare Trust Company, as escrow agent, in respect of 5,299,717 Company Shares (the " Value Escrow Agreement"). Under the terms of the Value Escrow Agreement, 10% of such escrowed securities were released upon the issuance of the final bulletin of the TSXV (the " Final Bulletin") with subsequent 15% releases occurring on each of the 6, 12, 18, 24, 30 and 36 months following the Final Bulletin, respectively. Certain shareholders of the Company are subject to seed share resale restrictions (" SSRRs") covering 9,320,988 Company Shares. These restrictions provide for an initial release of 20% on the date of the Final Bulletin, followed by additional 20% releases at 3, 6, and 9 months thereafter, with the final 20% released 12 months from the date of the Final Bulletin. About VVT Med Inc. VVT Med Inc. develops, manufactures, and commercializes minimally invasive, non-thermal, and non-tumescent solutions for the treatment of varicose veins. VVT Med Inc.'s products offer several key competitive advantages over traditional alternatives, including faster treatment times, reduced pain without the need for anesthesia, and quicker recovery and results. Cautionary Note Regarding Forward-Looking Statements This news release contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this document include, among others, statements relating to expectations regarding the effects of closing the Transaction, information relating to the business plans of the Company, the timing for the commencement of trading of the Company Shares on the TSXV and other statements that are not historical facts. Such statements and information reflect the current view of the Company. Risks and uncertainties that may cause actual results to differ materially from those contemplated in those forward-looking statements and information. The forward-looking information in this news release is based on certain assumptions and expectations about future events, including: the ability of the Company to continue as going concerns, ongoing approval of the Company's activities by relevant governmental and regulatory authorities, and its ability to maintain the listing requirements of the TSXV. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) the risk that the business plans of the Company may not be successfully executed or that unforeseen operational challenges may arise; (b) the risk that the market conditions or external factors may impact the ability of the Company to maintain the listing requirements of the TSXV; (c) the risk of changes in applicable laws, regulations, or government policies that could negatively impact or the future operations of the Company, (d) following completion of the Transaction, the Company may require additional financing from time to time in order to continue its operations which may not be available when needed or on acceptable terms and conditions acceptable; (e) the stock markets have experienced volatility that often has been unrelated to the performance of companies and these fluctuations may adversely affect the price of the Company's securities, regardless of its operating performance. The forward-looking information contained in this news release represents the expectations of the Company as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. The Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Hypebeast
02-06-2025
- Automotive
- Hypebeast
J Balvin's First Electric Motorcycle Is Part Sculpture, Part Anime
Last month,J Balvincelebrated his monumental 40th birthday with a casino-themed bash in Tuscany's rolling vineyards that was attended by the likes ofDaddy Yankee,Sofia Vergara, andZion. The star of the night, however, was not an A-lister but a one-of-one, bright-red, electric motorcycle, the first to come from Balvin's creative studio VVT (Vita Veloce Team), which he founded last year with designerMattias Gollin. Designed in collaboration withDAB Motors, the bubbly bike's arrival at the affair was quite the shock for Balvin.'He knew the DAB x VVT bike was coming,' said Gollin and Simon Dabadie, founder of DAB. 'But he had no idea when it would be ready. We kept the manufacturing of the motorcycle completely secret. Rolling it out at Castello di Velona, surrounded by friends—that moment felt special.' With AI-powered design tools and 3D-modeling capabilities, the prototype was brought to life in just three weeks. 'Part sculpture, part anime, and fully rideable,' the bike was built on DAB's1α platform with fully enclosed wheels, a sleek windshield, a deep matte red body, and all-over graphic sticker decorations — all in a bid to create a machine that looks like it came straight out of a popular Japanese animated movie. From a technical perspective, the two-seater motorcycle has a top speed of 130 km/hr, with a zero to 100% charging time of three hours and 30 minutes (compatible with both home sockets and Type 2 stations). The design also produces a multi-sensory experience, with sound-absorbing foam on the wheel covers and rims that creates a low-frequency tone, as well as atmospheric LED light strips in the wheels. 'It's cinematic, but functional, we wanted to build something that felt like riding through a dream,' Gollin and Dabadie concluded. See J Balvin's first electric motorcycle, made in collaboration with DAB Motors, above.
Yahoo
22-05-2025
- Business
- Yahoo
DXI Capital Corp. Files Filing Statement for RTO Transaction
Toronto, Ontario--(Newsfile Corp. - May 21, 2025) - DXI Capital Corp. (TSXV: DXI.H) ("DXI"), V.V.T. Med Ltd. ("VVT") and Exiteam Acquisition Corp. ("EAC", together with VVT and DXI, the "Parties") are pleased to announce that, further to DXI's press release dated March 25, 2025, DXI has filed a filing statement, dated effective May 15, 2025, with the TSX Venture Exchange (the "Exchange") in connection with its previously announced reverse take-over transaction (the "RTO") of DXI by VVT and EAC (the "Proposed Transaction") (the "Filing Statement"). The Filing Statement may be viewed on DXI's SEDAR+ profile at and contains complete information regarding the RTO. The resulting company following the completion of the Proposed Transaction is referred to as the "Resulting Issuer". Completion of the Proposed Transaction is still subject to a number of conditions including, but not limited to receipt of all requisite regulatory, stock exchange, court or governmental approvals, authorizations and consents and the conditions set out in the definitive agreement between the Parties dated September 30, 2024 (the "Definitive Agreement"). There can be no assurance that the Proposed Transaction will be completed on the terms proposed above or at all. Assuming all conditions are satisfied, the Parties anticipate closing of the Proposed Transaction in June 2025. DXI will issue a further press release once the Exchange issues its bulletin announcing its final approval of the Proposed Transaction and the date that trading of the common shares of the Resulting Issuer is expected to commence on the Exchange. The Resulting Issuer's trading symbol on the Exchange will be "VVTM". Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in securities of DXI should be considered highly speculative. Shares of DXI are currently halted from trading on the Exchange, and trading is not expected to resume until after closing of the Proposed Transaction in accordance with the policies of the Exchange. About VVT VVT develops, manufactures, and commercializes minimally invasive, non-thermal, and non-tumescent solutions for the treatment of varicose veins. VVT's products offer several key competitive advantages over traditional alternatives, including faster treatment times, reduced pain without the need for anesthesia, and quicker recovery and results. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This news release contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause DXI's actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this news release include, among others, statements relating to expectations regarding the anticipated completion of the Proposed Transaction (including all required approvals), that the closing of the Proposed Transaction will occur in June 2025, the satisfaction of conditions under the Definitive Agreement, and other statements that are not historical facts. The forward-looking information in this news release is based on certain assumptions and expectations about future events, including: the ability of the Parties to continue as going concerns, ongoing approval of the Parties' activities by relevant governmental and regulatory authorities, the Parties' capacity to meet all conditions for closing the Proposed Transaction, and their ability to fulfill the listing requirements of the TSXV. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) there is no assurance that the Parties to the Proposed Transaction will obtain the requisite director, shareholder and regulatory approvals for the Proposed Transaction; (b) the risk that the Proposed Transaction may not close within the anticipated timeframe or at all; (c) the potential inability to satisfy all conditions to closing, including the fulfillment of all regulatory and third-party approvals; (d) the risk that the business plans of the Parties may not be successfully executed or that unforeseen operational challenges may arise; (e) the risk that market conditions or external factors may impact the ability of the Parties to meet the listing requirements of the Exchange or face delays in commencement of trading; and (f) the risk of changes in applicable laws, regulations, or government policies that could negatively impact the Proposed Transaction or the future operations of the Resulting Issuer. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking information contained in this news release represents the expectations of DXI as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. DXI does not undertake to update this information at any particular time except as required in accordance with applicable laws. This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. DXI's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. DXI's common shares will remain halted until such time as permission to resume trading has been obtained from the Exchange. DXI is a reporting issuer in Alberta, British Columbia, Ontario and Québec. Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, EAC and VVT shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of DXI, EAC, VVT and the Resulting Issuer should be considered highly speculative. The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release. For more information, please contact: DXI CAPITAL CORP. Robert L. Hodgkinson, CEO Email: rhodgkinson@ Tel: (604) 638-5055 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in TSXV policies) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
Yahoo
21-05-2025
- Business
- Yahoo
DXI Capital Corp. Files Filing Statement for RTO Transaction
Toronto, Ontario--(Newsfile Corp. - May 21, 2025) - DXI Capital Corp. (TSXV: DXI.H) ("DXI"), V.V.T. Med Ltd. ("VVT") and Exiteam Acquisition Corp. ("EAC", together with VVT and DXI, the "Parties") are pleased to announce that, further to DXI's press release dated March 25, 2025, DXI has filed a filing statement, dated effective May 15, 2025, with the TSX Venture Exchange (the "Exchange") in connection with its previously announced reverse take-over transaction (the "RTO") of DXI by VVT and EAC (the "Proposed Transaction") (the "Filing Statement"). The Filing Statement may be viewed on DXI's SEDAR+ profile at and contains complete information regarding the RTO. The resulting company following the completion of the Proposed Transaction is referred to as the "Resulting Issuer". Completion of the Proposed Transaction is still subject to a number of conditions including, but not limited to receipt of all requisite regulatory, stock exchange, court or governmental approvals, authorizations and consents and the conditions set out in the definitive agreement between the Parties dated September 30, 2024 (the "Definitive Agreement"). There can be no assurance that the Proposed Transaction will be completed on the terms proposed above or at all. Assuming all conditions are satisfied, the Parties anticipate closing of the Proposed Transaction in June 2025. DXI will issue a further press release once the Exchange issues its bulletin announcing its final approval of the Proposed Transaction and the date that trading of the common shares of the Resulting Issuer is expected to commence on the Exchange. The Resulting Issuer's trading symbol on the Exchange will be "VVTM". Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in securities of DXI should be considered highly speculative. Shares of DXI are currently halted from trading on the Exchange, and trading is not expected to resume until after closing of the Proposed Transaction in accordance with the policies of the Exchange. About VVT VVT develops, manufactures, and commercializes minimally invasive, non-thermal, and non-tumescent solutions for the treatment of varicose veins. VVT's products offer several key competitive advantages over traditional alternatives, including faster treatment times, reduced pain without the need for anesthesia, and quicker recovery and results. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This news release contains statements that constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause DXI's actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements in this news release include, among others, statements relating to expectations regarding the anticipated completion of the Proposed Transaction (including all required approvals), that the closing of the Proposed Transaction will occur in June 2025, the satisfaction of conditions under the Definitive Agreement, and other statements that are not historical facts. The forward-looking information in this news release is based on certain assumptions and expectations about future events, including: the ability of the Parties to continue as going concerns, ongoing approval of the Parties' activities by relevant governmental and regulatory authorities, the Parties' capacity to meet all conditions for closing the Proposed Transaction, and their ability to fulfill the listing requirements of the TSXV. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors and risks include, among others: (a) there is no assurance that the Parties to the Proposed Transaction will obtain the requisite director, shareholder and regulatory approvals for the Proposed Transaction; (b) the risk that the Proposed Transaction may not close within the anticipated timeframe or at all; (c) the potential inability to satisfy all conditions to closing, including the fulfillment of all regulatory and third-party approvals; (d) the risk that the business plans of the Parties may not be successfully executed or that unforeseen operational challenges may arise; (e) the risk that market conditions or external factors may impact the ability of the Parties to meet the listing requirements of the Exchange or face delays in commencement of trading; and (f) the risk of changes in applicable laws, regulations, or government policies that could negatively impact the Proposed Transaction or the future operations of the Resulting Issuer. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking information contained in this news release represents the expectations of DXI as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. DXI does not undertake to update this information at any particular time except as required in accordance with applicable laws. This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. DXI's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. DXI's common shares will remain halted until such time as permission to resume trading has been obtained from the Exchange. DXI is a reporting issuer in Alberta, British Columbia, Ontario and Québec. Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable pursuant to Exchange requirements, EAC and VVT shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the Filing Statement, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of DXI, EAC, VVT and the Resulting Issuer should be considered highly speculative. The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release. For more information, please contact: DXI CAPITAL CORP. Robert L. Hodgkinson, CEO Email: rhodgkinson@ Tel: (604) 638-5055 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in TSXV policies) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
